Neuropsychological normalization with long-term atypical antipsychotic treatment: Results of a six-month randomized, double-blind comparison of ziprasidone vs. olanzapine

Journal of Neuropsychiatry and Clinical Neurosciences

Volumn 18, Issue 1, 2006, Pages 54-63

  Harvey, Philip D ^a   Bowie, Christopher R ^b   Loebel, Antony ^b  

^a MOUNT SINAI SCHOOL OF MEDICINE   (United States)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

ATYPICAL ANTIPSYCHOTIC AGENT; OLANZAPINE; ZIPRASIDONE;

ADULT; AGE; ARTICLE; ATTENTION; BRAIN FUNCTION; CLINICAL TRIAL; COGNITION; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; EDUCATION; FEMALE; HUMAN; LEARNING; LONG TERM CARE; MAJOR CLINICAL STUDY; MALE; NEUROPSYCHOLOGY; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SCHIZOPHRENIA; STANDARD; TASK PERFORMANCE; VERBAL BEHAVIOR; VERBAL MEMORY;

EID: 33244495522     PISSN: 08950172     EISSN: None     Source Type: Journal    
DOI: 10.1176/jnp.18.1.54     Document Type: Article

References (35)

1. Keefe RSE, Silva SG, Perkins DO, et al: The effects of atypical antipsychotic drugs on neurocognitive impairment in schizophrenia: a review and meta-analysis. Schizophr Bull 1999; 25:201-222
2. Harvey PD, Keefe RSE: Studies of cognitive change in patients with schizophrenia following novel antipsychotic treatment. Am J Psychiatry 2001; 158:176-184
3. Heinrichs RW, Zakzanis KK: Neurocognitive deficit in schizophrenia: a quantitative review of the evidence. Neuropsychology 1998; 12:426-444
4. Saykin AJ, Gur RC, Gur RE, et al: Neuropsychological function in schizophrenia: selective impairment in memory and learning. Arch Gen Psychiatry 1991; 48:618-624
5. Harvey PD, Green MF: Meltzer HX et al. The cognitive effects of risperidone and olanzapine in patients with schizoaffective disorder or schizophrenia. Psychopharmacology (Berl) 2003; 169:404-411
6. Bilder RM, Goldman RS, Volavka J, et al: Neurocognitive effects of clozapine, olanzapine, risperidone, and haloperidol in patients with chronic schizophrenia and schizoaffective disorder. Am J Psychiatry 2002; 159:1018-1028
7. Buchanan RW, Holstein C, Breier A: The comparative efficacy and long-term effect of clozapine treatment on neuropsychological test performance. Biol Psychiatry 1994; 36:717-725
8. Purdon SE, Jones BD, Slip E, et al: Neuropsychological change in early phase schizophrenia during 12 months of treatment with olanzapine, risperidone, or haloperidol. The Canadian collaborative group for research in schizophrenia. Arch Gen Psychiatry 2000; 57:249-258
9. Velligan DI, Newcomer J, Pultz J, et al: Does cognitive function improve with quetiapine in comparison to haloperidol? Schizophr Res 2002; 53:239-248
10. Harvey PD, Napolitano JA, Mao, L. et al: Comparative effects of risperidone and olanzapine on cognition in elderly patients with schizophrenia or schizoaffective disorder. Int J Geriatr Psychiatr 2003; 18:820-829
11. Harvey PD, Siu S, Romano S: A double-blind randomized comparison of ziprasidone vs. olanzapine for cognition in schizophrenia. Psychopharmacology (Berl) 2004; 172:324-332
12. Kay SR. Positive and negative syndromes in schizophrenia. New York: Brunner/Mazel, 1991
13. Taylor MJ, Heaton RK: Sensitivity and specificity of wais-III/WMS-III demographically corrected factor scores in neuropsychological assessment. J Int Neuropsychol Soc 2001; 7:867-874
14. Cornblatt BA, Lenzenweger MF, Erlenmeyer-Kimling L: The continuous performance test, identical pairs version: II. Contrasting attentional profiles in schizophrenic and depressed patients Psychiatr Res 1989; 29:65-85
15. Green MF, Marshall BD, Jr, Wirshing WC, et al: Does risperidone improve verbal working memory in treatment resistant schizophrenia? Am J Psychiatry 1997; 154:799-804
16. Reitan RM, Wolfson D. The Halstead-Reitan neuropsychological test battery: Theory and clinical interpretation. 2nd ed. Tucson, Ariz: Neuropsychology Press, 1993
17. Lezak MD. Neuropsychological assessment. (1997). 3ed. New York, Oxford University Press.
18. Heaton RK, Chelune CJ, Talley JL, Kay GG, Curtiss G (1993). Wisconsin Card Sorting Test Manual-Revised and expanded. Odessa, Fla: Psychological Assessment Resources.
19. Spreen O, Strauss E. A compendium of neuropsychological tests and norms. 2ed. New York: Oxford University Press, 1998
20. Gladsjo JA, Schuman CC, Evans JD, et al: norms for letter and category fluency: demographic corrections for age, education, and ethnicity. Assessment 1999; 6:147-178
21. Blyer CR, Gold JM. Cognitive effects of typical antipsychotic medication treatment: another look. In Sharma T and Harvey PD (Eds.). Cognition in schizophrenia, pp 241-265. New York: Oxford University Press, 2000
22. Hawkins KA, Wexler BA: California verbal learning test practice effects in a schizophrenia sample. Schizophr Res 1999; 39:73-78
23. Barnes TRE: A rating scale for drug-induced akathisia. Br J Psychiat 1989; 154:672-66
24. Chouinard G, Ross-Chouinard A, et al: Extrapyramidal symptom rating scale. Can J Neurol Sci 1980; 7:233
25. US Dept of Health, Education, and Welfare. The Abnormal Involuntary Movement Scale. Rockville, Md: US Dept of Health, Education, and Welfare. Publication ADM 76-338, 1976
26. Meltzer HY, Alphs L, Green AI, et al: Clozapine treatment for suicidality in schizophrenia: international suicide prevention trial (Inter sept). Arch Gen Psychiatry 2003; 60:82-91
27. Harvey PD, Meltzer HY, Simpson GS, et al: Improvement in cognitive function following a switch to ziprasidone from conventional antipsychotics, olanzapine, or risperidone in outpatients with schizophrenia. Schizophr Res 2004; 66:101-114
28. Weiden PJ, Simpson GS, Potkin SG, et al: Effectiveness of switching to ziprasidone for stable but symptomatic outpatients with schizophrenia. J Clin Psychiatry 2003; 64:580-588
29. Harvey PD, Palmer BA, Heaton RK, et al. Stability of Cognitive Performance in Older Patients with Schizophrenia: An Eight-Week Test-Retest study. Am J Psychiatry, in press
30. Harvey PD, Moriarty PJ, Serper MR, et al: Practice-related improvement in information processing with novel antipsychotic treatment. Schizophr Res 2000; 46:139-148
31. Medalia A, Revheim N, Casey M: Remediation of memory disorders in schizophrenia. Psychol Med 2000; 30:1451-1459
32. Medalia A, Aluma M, Tryon W, et al: Effectiveness of attention training in schizophrenia. Schizophr Bull 1998; 24:147-152
33. Pilling S, Bebbington P, Kuipers E, et al: Psychological treatment in schizophrenia: II. meta-analyses of randomized controlled trials of social skills training and cognitive remediation. Psychol Med 2002; 35:783-791
34. Bell MD, Fiszdon J, Bryson G, et al: Effects of neurocognitive enhancement therapy in schizophrenia: normalization of memory performance. Cog Neuropsychiatry 2004; 9:199-211
35. Heinrichs DW, Hanlon TE, Carpenter WT Jr: The quality of life scale: an instrument for rating the schizophrenic deficit syndrome. Schizophr Bull 1984; 10:388-398